| Dr Theodore William James, MD | |
|
417 State St Ste 121, Bangor, ME 04401-6630 | |
| (207) 973-4266 | |
| Not Available |
| Full Name | Dr Theodore William James |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 11 Years |
| Location | 417 State St Ste 121, Bangor, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003159559 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD24132 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bangor, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainegeneral Medical Center | 1254245715 | 487 |
| St Joseph Hospital | 6406766336 | 155 |
News Archive
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.
The Republican strategy is to split the vast middle and working classes - pitting unionized workers against nonunionized, public-sector workers against nonpublic, older workers within sight of Medicare and Social Security against younger workers who don't believe these programs will be there for them and the poor against the working middle class.
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).
When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.
Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.
› Verified 8 days ago
| Entity Name | Mainegeneral Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669423380 PECOS PAC ID: 1254245715 Enrollment ID: O20031118000718 |
News Archive
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.
The Republican strategy is to split the vast middle and working classes - pitting unionized workers against nonunionized, public-sector workers against nonpublic, older workers within sight of Medicare and Social Security against younger workers who don't believe these programs will be there for them and the poor against the working middle class.
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).
When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.
Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.
› Verified 8 days ago
| Entity Name | St Joseph Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154321545 PECOS PAC ID: 6406766336 Enrollment ID: O20040604000895 |
News Archive
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.
The Republican strategy is to split the vast middle and working classes - pitting unionized workers against nonunionized, public-sector workers against nonpublic, older workers within sight of Medicare and Social Security against younger workers who don't believe these programs will be there for them and the poor against the working middle class.
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).
When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.
Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theodore William James, MD 43 Whiting Hill Rd Ste 300, Brewer, ME 04412-1006 Ph: (207) 973-5000 | Dr Theodore William James, MD 417 State St Ste 121, Bangor, ME 04401-6630 Ph: (207) 973-4266 |
News Archive
New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.
The Republican strategy is to split the vast middle and working classes - pitting unionized workers against nonunionized, public-sector workers against nonpublic, older workers within sight of Medicare and Social Security against younger workers who don't believe these programs will be there for them and the poor against the working middle class.
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).
When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.
Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.
› Verified 8 days ago
Eddy Karnabi, MD PHD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Fnu Kaleemullah, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7314 | |
Sverrir I Gunnarsson, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Northeast Dr, Bangor, ME 04401 Phone: 207-275-3800 | |
Liga Yusvirazi, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 360 Broadway, Bangor, ME 04401 Phone: 207-907-3283 | |
Ilsa Annetta Shulman, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-3300 Fax: 207-907-1923 | |
Dr. Michael Paul Sighinolfi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 360 Broadway Ste 100, Bangor, ME 04401 Phone: 207-907-3550 Fax: 207-907-3562 |